Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.70 |
| ▸ | CA2 | P00918 | 3/20 | 0.67 |
| ▸ | CA12 | O43570 | 2/20 | 0.67 |
| ▸ | CA1 | P00915 | 2/20 | 0.67 |
| ▸ | CA9 | Q16790 | 2/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | CES1 | P23141 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | CES2 | O00748 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | DAO | P14920 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2593117 | 1.00 | NFE2L2 (0.70) | NFE2L2CA2CA12CA1CA9 | |
| SCHEMBL3829338 | 1.00 | NFE2L2 (0.70) | NFE2L2CA2CA12CA1CA9 | |
| SCHEMBL9781094 | 0.84 | NFE2L2 (0.70) | NFE2L2CA2CA12CA1CA9 | |
| SCHEMBL3244802 | 0.82 | NFE2L2 (1.00) | NFE2L2CA2CA12CA1CA9 | |
| SCHEMBL6426228 | 0.82 | NFE2L2 (1.00) | NFE2L2CA2CA12CA1CA9 | |
| SCHEMBL464633 | 0.82 | NFE2L2 (1.00) | NFE2L2CA2CA12CA1CA9 | |
| SCHEMBL7598129 | 0.80 | CA2 (0.54) | NFE2L2CA2CA12CA1CA9 | |
| SCHEMBL14462260 | 0.80 | NFE2L2 (0.64) | NFE2L2CA2CA12CA1CA9 | |
| SCHEMBL668443 | 0.80 | NFE2L2 (0.64) | NFE2L2CA2CA12CA1CA9 | |
| SCHEMBL11498687 | 0.80 | NFE2L2 (0.64) | NFE2L2CA2CA12CA1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 126 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115407010-B | Method for identifying active ingredients in edible betel nuts by using wide-range targeted metabonomics technology | 中国检验检疫科学研究院 | 2024-01-23 | — | — | CN | claimed |
| CN-115407010-A | Method for identifying active ingredients in edible areca nuts by utilizing extensive targeted metabonomics technology | 中国检验检疫科学研究院 | 2022-11-29 | — | — | CN | claimed |
| JP-3246251-A | — | — | None | — | — | JP | disclosed |
| US-20240032544-A1 | IDENTIFICATION OF AGRICULTURALLY BENEFICIAL MICROBIAL COMPOSITIONS AND USES THEREOF | BIOCONSORTIA, INC. | 2024-02-01 | — | — | US | disclosed |
| CN-115407010-B | Method for identifying active ingredients in edible betel nuts by using wide-range targeted metabonomics technology | 中国检验检疫科学研究院 | 2024-01-23 | — | — | CN | disclosed |
| US-11723985-B2 | Protein delivery to membranes | CYTOSEEK LIMITED (GB) | 2023-08-15 | — | — | US | disclosed |
| EP-4203689-A2 | IDENTIFICATION OF AGRICULTURALLY BENEFICIAL MICROBIAL COMPOSITIONS AND USES THEREOF | BioConsortia, Inc. (US) | 2023-07-05 | — | — | EP | disclosed |
| WO-2023081775-A1 | COMBINATION INHIBITORS FOR TREATING FIBROSIS | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2023-05-11 | — | — | WO | disclosed |
| CN-115407010-A | Method for identifying active ingredients in edible areca nuts by utilizing extensive targeted metabonomics technology | 中国检验检疫科学研究院 | 2022-11-29 | — | — | CN | disclosed |
| WO-2022047396-A2 | IDENTIFICATION OF AGRICULTURALLY BENEFICIAL MICROBIAL COMPOSITIONS AND USES THEREOF | BIOCONSORTIA, INC. (US) | 2022-03-03 | — | — | WO | disclosed |
| US-20210060174-A1 | PROTEIN DELIVERY TO MEMBRANES | CYTOSEEK LIMITED (GB) | 2021-03-04 | — | — | US | disclosed |
| US-20030092629-A1 | Inhibitors of memapsin 2 and use thereof | OKLAHOMA MEDICAL RESEARCH FOUNDATION | 2003-05-15 | — | — | US | disclosed |
| EP-1114143-A4 | STREPTOCOCCAL C BETA PROTEIN COMPOSITIONS | NORTH AMERICAN VACCINE INC (CA) | 2003-05-07 | — | — | EP | disclosed |
| US-6326163-B1 | MONITORING GENE EXPRESSION IN MUTANT AND WILDTYPE SAMPLE; OBTAIN SAMPLE, CONCENTRATE PREFERENTIAL PROTEIN, DETERMINE WEIGHT OF PROTEIN, EVALUATE GENE EXPRESSION | PHARIS BIOTEC GMBH (DE) | 2001-12-04 | — | — | US | disclosed |
| EP-1114143-A1 | STREPTOCOCCAL C BETA PROTEIN COMPOSITIONS | NORTH AMERICAN VACCINE, INC. (CA) | 2001-07-11 | — | — | EP | disclosed |
| US-6140639-A | System and method for on-line coupling of liquid capillary separations with matrix-assisted laser desorption/ionization mass spectrometry | VANDERBILT UNIVERSITY (US) | 2000-10-31 | — | — | US | disclosed |
| WO-2000015760-A1 | STREPTOCOCCAL C BETA PROTEIN COMPOSITIONS | NORTH AMERICAN VACCINE, INC. (US) | 2000-03-23 | — | — | WO | disclosed |
| EP-0496793-A1 | ENHANCED CHEMILUMINESCENT ASSAY. | BRITISH TECH GROUP (GB) | 1992-08-05 | — | — | EP | disclosed |
| JP-H03246251-A | ARYLIDENE GLYCOLATOPLATINUM COMPLEX COMPOUND | SAGAMI CHEM RES CENTER | 1991-11-01 | — | — | JP | disclosed |
| WO-1991005872-A1 | ENHANCED CHEMILUMINESCENT ASSAY | BRITISH TECHNOLOGY GROUP LTD (GB) | 1991-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092629-A1 | Inhibitors of memapsin 2 and use thereof | MMEL1, MME, METAP2 | NFE2L2 4111/4885CA2 641/4885CA12 406/4885 |
| US-11723985-B2 | Protein delivery to membranes | PCTP, SCAMP3, SCAMP2 | NFE2L2 4788/4885CA2 2225/4885CA12 1514/4885 |
| US-20210060174-A1 | PROTEIN DELIVERY TO MEMBRANES | SCAMP3, SCAMP2, PCTP | NFE2L2 4791/4885CA2 1993/4885CA12 1493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.